Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
Multiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refractory (R/R) disease course, which poses a major therapeutic challenge. New therapies, including BRAF V600E mutation targeting, may become a new treatment option for R/R MM. In combination with mitogen-a...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2020/8894031 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554490911260672 |
|---|---|
| author | Rūta Čepulytė Andrius Žučenka Valdas Pečeliūnas |
| author_facet | Rūta Čepulytė Andrius Žučenka Valdas Pečeliūnas |
| author_sort | Rūta Čepulytė |
| collection | DOAJ |
| description | Multiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refractory (R/R) disease course, which poses a major therapeutic challenge. New therapies, including BRAF V600E mutation targeting, may become a new treatment option for R/R MM. In combination with mitogen-activated protein kinase inhibitors (MEKi), BRAF inhibitors (BRAFi) could provide better tailored clinical management, although experience in this field is lacking. To this date, there is only one case describing R/R MM treatment with BRAFi vemurafenib and MEKi cobimetinib. This is the first case presenting a R/R MM patient treated with BRAFi dabrafenib and MEKi trametinib. |
| format | Article |
| id | doaj-art-51a67998993a4f089255f48e364482d8 |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-51a67998993a4f089255f48e364482d82025-02-03T05:51:16ZengWileyCase Reports in Hematology2090-65602090-65792020-01-01202010.1155/2020/88940318894031Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E MutationRūta Čepulytė0Andrius Žučenka1Valdas Pečeliūnas2Vilnius University Hospital Santaros Klinikos, Center of Hematology, Oncology and Transfusion Medicine, Santariškių 2, Vilnius 08661, LithuaniaVilnius University Hospital Santaros Klinikos, Center of Hematology, Oncology and Transfusion Medicine, Santariškių 2, Vilnius 08661, LithuaniaVilnius University Hospital Santaros Klinikos, Center of Hematology, Oncology and Transfusion Medicine, Santariškių 2, Vilnius 08661, LithuaniaMultiple myeloma (MM) is an incurable plasma cell neoplasia characterized by relapsed and/or refractory (R/R) disease course, which poses a major therapeutic challenge. New therapies, including BRAF V600E mutation targeting, may become a new treatment option for R/R MM. In combination with mitogen-activated protein kinase inhibitors (MEKi), BRAF inhibitors (BRAFi) could provide better tailored clinical management, although experience in this field is lacking. To this date, there is only one case describing R/R MM treatment with BRAFi vemurafenib and MEKi cobimetinib. This is the first case presenting a R/R MM patient treated with BRAFi dabrafenib and MEKi trametinib.http://dx.doi.org/10.1155/2020/8894031 |
| spellingShingle | Rūta Čepulytė Andrius Žučenka Valdas Pečeliūnas Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation Case Reports in Hematology |
| title | Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation |
| title_full | Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation |
| title_fullStr | Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation |
| title_full_unstemmed | Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation |
| title_short | Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation |
| title_sort | combination of dabrafenib and trametinib for the treatment of relapsed and refractory multiple myeloma harboring braf v600e mutation |
| url | http://dx.doi.org/10.1155/2020/8894031 |
| work_keys_str_mv | AT rutacepulyte combinationofdabrafenibandtrametinibforthetreatmentofrelapsedandrefractorymultiplemyelomaharboringbrafv600emutation AT andriuszucenka combinationofdabrafenibandtrametinibforthetreatmentofrelapsedandrefractorymultiplemyelomaharboringbrafv600emutation AT valdaspeceliunas combinationofdabrafenibandtrametinibforthetreatmentofrelapsedandrefractorymultiplemyelomaharboringbrafv600emutation |